Skip to main content
SpringerLink
Log in

Regulation: The FDA is overcautious on consumer genomics

  • Comment
  • Published:

From Nature

View current issue Submit your manuscript

A US drug-agency clampdown is unwarranted without evidence of harm, say Robert C. Green and Nita A. Farahany.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Carver, K. H. Food Drug Law J. 63, 151–215 (2008).

  2. Kalf, R. R. J. et al. Genet. Med. http://dx.doi.org/10.1038/gim.2013.80 (2013).

  3. Swan, M. Genet. Med. 12, 279–288 (2010).

    Article  Google Scholar 

  4. Bloss, C. S. et al. Genet. Med. 12, 556–566 (2010).

    Article  Google Scholar 

  5. Bloss, C. S., Schork, N. J. & Topol, E. J. N. Engl. J. Med. 364, 524–534 (2011).

  6. Green, R. C. et al. N. Engl. J. Med. 361, 245–254 (2009).

    Article  CAS  Google Scholar 

  7. Lautenbach, D. M., Christensen, K. D., Sparks, J. A. & Green, R. C. Annu. Rev. Genomics Hum. Genet. 14, 491–513 (2013).

  8. Kaufman, D. J., Bollinger, J. M., Dvoskin, R. L. & Scott, J. A. J. Genet. Couns. 21, 413–422 (2012).

    Article  Google Scholar 

  9. Francke, U. et al. PeerJ 1, e8 (2013).

    Article  Google Scholar 

  10. Topol, E. The Creative Destruction of Medicine (Basic, 2012).

Download references

Author information

Authors and Affiliations

  1. Robert C. Green is in the Division of Genetics, Brigham and Women’s Hospital and Harvard Medical School, and the Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts.,

    Robert C Green

  2. Nita A. Farahany is at the Duke University School of Law and the Duke Institute for Genome Sciences and Policy, Durham, North Carolina.,

    Nita A Farahany

Authors
  1. Robert C Green
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nita A Farahany
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

R.C.G. leads several NIH research projects on genetic disclosure including one completed project, the Impact of Personal Genomics or PGen Study, (R01-HG005092) Scientists from two companies, 23andMe and Pathway Genomics interact with this study but have no control over data, analysis or publications. R.C.G. has, without compensation, contributed self-scripted, non-exclusive educational material to the 23andMe website. R.C.G. has not received personal financial support from any of the above entities; he has received support from the Brin-Wojcicki Foundation for an unrelated sequencing project.

Related links

Rights and permissions

Reprints and permissions

About this article

Cite this article

Green, R., Farahany, N. Regulation: The FDA is overcautious on consumer genomics. Nature 505, 286–287 (2014). https://doi.org/10.1038/505286a

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/505286a

  • Springer Nature Limited

This article is cited by

Search

Navigation